Edition:
United Kingdom

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

121.03USD
8:59pm GMT
Change (% chg)

$-5.42 (-4.29%)
Prev Close
$126.45
Open
$127.50
Day's High
$134.00
Day's Low
$120.78
Volume
87,207
Avg. Vol
158,761
52-wk High
$134.00
52-wk Low
$18.18

Chart for

About

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro,... (more)

Overall

Beta: --
Market Cap(Mil.): $725.82
Shares Outstanding(Mil.): 20.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Anaptysbio qtrly loss per share $0.45‍​

* Anaptysbio announces third quarter 2017 financial results and provides pipeline updates

07 Nov 2017

BRIEF-AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results

* Anaptysbio reports positive anb019 top-line phase 1 clinical trial results

06 Nov 2017

BRIEF-AnaptysBio prices public offering of 3 mln shares at $68.50 per share

* Says public offering of 3.00 million common shares priced at $68.50per share Source text for Eikon: Further company coverage:

13 Oct 2017

BRIEF-AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis

* AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis

10 Oct 2017

BRIEF-‍adage Capital reports a 6.05 percent passive stake in AnaptysBio

* ‍Adage Capital Partners GP reports a 6.05 percent passive stake in AnaptysBio Inc​ as of September 22 - SEC filing​ Source text: (http://bit.ly/2yTdILI) Further company coverage:

02 Oct 2017

Earnings vs. Estimates